IMRX
Immuneering Corp
Key Financials
Operating Income
$-59375969
↑ 7.3%
Gross Profit
$0
↓ 100.0%
Revenue
$0
↓ 100.0%
Net Income
$-56024898
↑ 8.2%
Cash & Equivalents
$128.6M
↑ 255.9%
EPS (Diluted)
$-1.27
↑ 37.7%
Shareholders' Equity
$218.5M
↑ 427.9%
Total Liabilities
$13.5M
↑ 19.2%
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| 10-Q | 8/5/2026 | View on SEC |
| 8-K | 8/5/2026 | View on SEC |
| SCHEDULE 13G | 7/28/2026 | View on SEC |
| 4 | 7/17/2026 | View on SEC |
| 3 | 7/16/2026 | View on SEC |
| 4 | 6/24/2026 | View on SEC |
| 4 | 6/16/2026 | View on SEC |
| 8-K | 6/15/2026 | View on SEC |
| 4 | 6/11/2026 | View on SEC |
| 4 | 6/11/2026 | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | IMRX |
| Company Name | Immuneering Corp |
| CIK | 1790340 |
| Sector | Pharmaceutical Preparations |
| Industry | Non-accelerated filer Smaller reporting company Emerging growth company |
| Exchange | Nasdaq |
| SIC Code | 2834 |
| SIC Description | Pharmaceutical Preparations |
| Entity Type | operating |
| Fiscal Year End | 1231 |
| State of Incorporation | DE |
| Phone | 617-500-8080 |